Go Pro

Solventum (SOLV) Competitors

Solventum logo
$89.64 +1.03 (+1.16%)
As of 08/21/2026 03:58 PM Eastern

SOLV vs. MDLN, ALC, WST, COO, and ALGN

Should you buy Solventum stock or one of its competitors? Solventum's main competitors and comparable companies include Medline (MDLN), Alcon (ALC), West Pharmaceutical Services (WST), Cooper Companies (COO), and Align Technology (ALGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Solventum compare to Medline?

Solventum (NYSE:SOLV) and Medline (NASDAQ:MDLN) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Medline had 11 more articles in the media than Solventum. MarketBeat recorded 15 mentions for Medline and 4 mentions for Solventum. Solventum's average media sentiment score of 0.91 beat Medline's score of 0.15 indicating that Solventum is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Solventum
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Medline
4 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

Solventum has a net margin of 17.26% compared to Medline's net margin of 0.00%. Solventum's return on equity of 25.09% beat Medline's return on equity.

Company Net Margins Return on Equity Return on Assets
Solventum17.26% 25.09% 8.78%
Medline N/A N/A N/A

Solventum has higher earnings, but lower revenue than Medline. Solventum is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Solventum$8.33B1.83$1.56B$8.1810.96
Medline$29.94B1.50$1.16B$0.7943.37

Solventum currently has a consensus price target of $91.64, indicating a potential upside of 2.23%. Medline has a consensus price target of $47.42, indicating a potential upside of 38.42%. Given Medline's stronger consensus rating and higher possible upside, analysts plainly believe Medline is more favorable than Solventum.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Solventum
1 Sell rating(s)
4 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.54
Medline
1 Sell rating(s)
5 Hold rating(s)
21 Buy rating(s)
2 Strong Buy rating(s)
2.83

Summary

Solventum and Medline tied by winning 7 of the 14 factors compared between the two stocks.

How does Solventum compare to Alcon?

Alcon (NYSE:ALC) and Solventum (NYSE:SOLV) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Solventum has lower revenue, but higher earnings than Alcon. Solventum is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alcon$10.40B3.50$980M$1.3156.18
Solventum$8.33B1.83$1.56B$8.1810.96

Alcon presently has a consensus target price of $84.96, indicating a potential upside of 15.46%. Solventum has a consensus target price of $91.64, indicating a potential upside of 2.23%. Given Alcon's stronger consensus rating and higher probable upside, analysts clearly believe Alcon is more favorable than Solventum.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alcon
1 Sell rating(s)
6 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.63
Solventum
1 Sell rating(s)
4 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.54

Alcon has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Solventum has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market.

53.9% of Alcon shares are owned by institutional investors. 1.5% of Alcon shares are owned by insiders. Comparatively, 0.2% of Solventum shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Solventum had 2 more articles in the media than Alcon. MarketBeat recorded 4 mentions for Solventum and 2 mentions for Alcon. Solventum's average media sentiment score of 0.91 beat Alcon's score of 0.42 indicating that Solventum is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alcon
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Solventum
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Solventum has a net margin of 17.26% compared to Alcon's net margin of 5.92%. Solventum's return on equity of 25.09% beat Alcon's return on equity.

Company Net Margins Return on Equity Return on Assets
Alcon5.92% 7.29% 5.09%
Solventum 17.26%25.09%8.78%

Summary

Alcon beats Solventum on 10 of the 17 factors compared between the two stocks.

How does Solventum compare to West Pharmaceutical Services?

West Pharmaceutical Services (NYSE:WST) and Solventum (NYSE:SOLV) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

93.9% of West Pharmaceutical Services shares are owned by institutional investors. 0.6% of West Pharmaceutical Services shares are owned by company insiders. Comparatively, 0.2% of Solventum shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, West Pharmaceutical Services had 12 more articles in the media than Solventum. MarketBeat recorded 16 mentions for West Pharmaceutical Services and 4 mentions for Solventum. West Pharmaceutical Services' average media sentiment score of 1.57 beat Solventum's score of 0.91 indicating that West Pharmaceutical Services is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
West Pharmaceutical Services
16 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Solventum
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

West Pharmaceutical Services has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Solventum has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market.

West Pharmaceutical Services currently has a consensus price target of $368.08, indicating a potential upside of 4.29%. Solventum has a consensus price target of $91.64, indicating a potential upside of 2.23%. Given West Pharmaceutical Services' stronger consensus rating and higher probable upside, equities analysts clearly believe West Pharmaceutical Services is more favorable than Solventum.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
West Pharmaceutical Services
0 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.87
Solventum
1 Sell rating(s)
4 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.54

Solventum has a net margin of 17.26% compared to West Pharmaceutical Services' net margin of 16.98%. Solventum's return on equity of 25.09% beat West Pharmaceutical Services' return on equity.

Company Net Margins Return on Equity Return on Assets
West Pharmaceutical Services16.98% 20.11% 14.83%
Solventum 17.26%25.09%8.78%

Solventum has higher revenue and earnings than West Pharmaceutical Services. Solventum is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$3.07B8.08$493.70M$7.8145.19
Solventum$8.33B1.83$1.56B$8.1810.96

Summary

West Pharmaceutical Services beats Solventum on 12 of the 17 factors compared between the two stocks.

How does Solventum compare to Cooper Companies?

Solventum (NYSE:SOLV) and Cooper Companies (NASDAQ:COO) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

In the previous week, Cooper Companies had 31 more articles in the media than Solventum. MarketBeat recorded 35 mentions for Cooper Companies and 4 mentions for Solventum. Cooper Companies' average media sentiment score of 0.97 beat Solventum's score of 0.91 indicating that Cooper Companies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Solventum
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cooper Companies
20 Very Positive mention(s)
6 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Positive

Solventum has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Cooper Companies has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

Solventum has higher revenue and earnings than Cooper Companies. Solventum is trading at a lower price-to-earnings ratio than Cooper Companies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Solventum$8.33B1.83$1.56B$8.1810.96
Cooper Companies$4.09B3.63$374.90M$1.1864.59

Solventum has a net margin of 17.26% compared to Cooper Companies' net margin of 5.57%. Solventum's return on equity of 25.09% beat Cooper Companies' return on equity.

Company Net Margins Return on Equity Return on Assets
Solventum17.26% 25.09% 8.78%
Cooper Companies 5.57%10.88%7.27%

24.4% of Cooper Companies shares are owned by institutional investors. 0.2% of Solventum shares are owned by company insiders. Comparatively, 2.1% of Cooper Companies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Solventum currently has a consensus target price of $91.64, indicating a potential upside of 2.23%. Cooper Companies has a consensus target price of $81.64, indicating a potential upside of 7.11%. Given Cooper Companies' higher possible upside, analysts plainly believe Cooper Companies is more favorable than Solventum.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Solventum
1 Sell rating(s)
4 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.54
Cooper Companies
3 Sell rating(s)
6 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.35

Summary

Cooper Companies beats Solventum on 9 of the 17 factors compared between the two stocks.

How does Solventum compare to Align Technology?

Align Technology (NASDAQ:ALGN) and Solventum (NYSE:SOLV) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

Solventum has a net margin of 17.26% compared to Align Technology's net margin of 9.99%. Solventum's return on equity of 25.09% beat Align Technology's return on equity.

Company Net Margins Return on Equity Return on Assets
Align Technology9.99% 15.86% 10.32%
Solventum 17.26%25.09%8.78%

Align Technology has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market. Comparatively, Solventum has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

Align Technology presently has a consensus price target of $206.36, indicating a potential upside of 26.95%. Solventum has a consensus price target of $91.64, indicating a potential upside of 2.23%. Given Align Technology's stronger consensus rating and higher possible upside, equities research analysts plainly believe Align Technology is more favorable than Solventum.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Align Technology
0 Sell rating(s)
6 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.67
Solventum
1 Sell rating(s)
4 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.54

Solventum has higher revenue and earnings than Align Technology. Solventum is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Align Technology$4.03B2.89$410.35M$5.7528.27
Solventum$8.33B1.83$1.56B$8.1810.96

In the previous week, Align Technology had 8 more articles in the media than Solventum. MarketBeat recorded 12 mentions for Align Technology and 4 mentions for Solventum. Align Technology's average media sentiment score of 1.18 beat Solventum's score of 0.91 indicating that Align Technology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Align Technology
9 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Solventum
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

88.4% of Align Technology shares are owned by institutional investors. 0.8% of Align Technology shares are owned by company insiders. Comparatively, 0.2% of Solventum shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Align Technology beats Solventum on 11 of the 16 factors compared between the two stocks.

Get Solventum News Delivered to You Automatically

Sign up to receive the latest news and ratings for SOLV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SOLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SOLV vs. The Competition

MetricSolventumHealthcare Equipment & Supplies IndustryHealthcare SectorNYSE Exchange
Market Cap$15.25B$6.02B$7.37B$24.30B
Dividend YieldN/A1.75%2.53%3.70%
P/E Ratio10.9626.67272.6030.31
Price / Sales1.8345.39618.9619.91
Price / Cash9.9733.2478.6232.49
Price / Book3.186.2313.056.77
Net Income$1.56B$150.07M$3.47B$1.07B
7 Day Performance1.26%0.69%2.09%-0.65%
1 Month Performance15.98%8.91%6.64%3.38%
1 Year Performance22.03%8.07%25.02%14.90%

Solventum Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SOLV
Solventum
2.7486 of 5 stars
$89.64
+1.2%
$91.64
+2.2%
+22.0%$15.25B$8.33B10.9620,000
MDLN
Medline
3.8374 of 5 stars
$34.88
-2.4%
$47.42
+36.0%
N/A$46.99B$28.43B44.1545,000
ALC
Alcon
3.1978 of 5 stars
$72.50
-2.4%
$84.63
+16.7%
-10.3%$36.73B$10.40B55.3425,942
WST
West Pharmaceutical Services
4.0693 of 5 stars
$346.69
-0.8%
$368.08
+6.2%
+42.6%$24.59B$3.07B44.3910,800
COO
Cooper Companies
2.8047 of 5 stars
$75.10
-1.4%
$81.64
+8.7%
+1.3%$14.86B$4.09B63.6415,000

Related Companies and Tools


This page (NYSE:SOLV) was last updated on 8/23/2026 by MarketBeat.com Staff.
From Our Partners